Collaborative Research Center granted DFG funding for a further four years.
The German Research Foundation (DFG) will fund the Collaborative Research Center/Transregio (CRC/TR) "FungiNet" for four more years with approximately ten million Euro. In the only CRC studying human pathogenic fungi, scientists in Jena and Würzburg will investigate infection processes and novel therapeutic options.
Fungal infections are a major challenge for modern medicine. Elderly or immunocompromised patients, for example those with leukemia or requiring organ transplantation, are particularly at risk. These life-threatening infections are often diagnosed too late, treatment options are extremely limited, and the pathogens are increasingly resistant to available drugs. COVID-19 exacerbates the problem: "SARS-CoV-2 infected patients have a higher risk of developing fungal infections starting in the respiratory tract. The severity of the diseases also increases dramatically," warns Axel Brakhage, spokesman of the Collaborative Research Center.
Understanding life-threatening fungal infections
Scientists and physicians from Jena and Würzburg have therefore joined forces to better understand life-threatening infections and to develop new, urgently needed therapeutic approaches. The Collaborative Research Center/Transregio 124 Pathogenic Fungi and their Human Host: Networks of Interaction - "FungiNet" for short - was established in 2013 and has been continuously funded by the DFG. Its research focus on human pathogenic fungi is unique in Europe. In the first two funding periods, experts from the fields of microbiology, immunology, clinical research, bioinformatics, and chemistry jointly conducted many fundamental studies on the two model pathogens Aspergillus fumigatus and Candida albicans which cause most severe fungal infections in Europe.
For example, the researchers developed a new microscopy method to study the spread of the mold Aspergillus fumigatus in the lungs. Using light sheet microscopy, the entire lung can be viewed and the interaction between immune cells and fungus mapped on a 3D map.
In addition, the FungiNet partners were able to gain important insights into infections caused by the yeast Candida albicans. For example, they elucidated how this fungus can be killed by certain immune cells and how the microbiome in the intestine influences the spread of the fungus.
Developing clinical applications
"In recent years, we have learned a lot about the mechanisms of infection. We have identified so-called virulence factors - i.e. the disease-causing properties of fungi - and now have a much better understanding of how the immune system reacts to them," sums up Brakhage, director of the Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute - who also holds the chair for Microbiology and Molecular Biology at Friedrich Schiller University Jena.
"Our focus in the third funding phase is clearly on translation, the transfer of these findings into clinical applications to patients," the CRC spokesperson further emphasizes. Therefore, the FungiNet team will be strengthened by scientists from the clinical environment in the upcoming funding phase. The researchers want to identify so-called biomarkers to improve the difficult diagnosis of fungal infections. Furthermore, they will evaluate new therapeutic approaches in preclinical studies. Great expectations lie on certain cells of the immune system, such as T cells or natural killer cells. They are capable of learning and can be trained to fight invading fungal pathogens. This includes the evaluation of extracellular vesicles from immune cells as therapeutic option. The CRC FungiNet also aims to drive technological advances in bioinformatics and imaging and to develop virtual infection models.